Adnexal tumours of the skin as markers of cancer-prone syndromes

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue 4, 2010, Pages 379-387

  Kanitakis, J ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Adnexal tumours; Birt Hogg Dub syndrome; Cancer prone syndromes; Cowden's syndrome; Epidermoid cysts; Fibrofolliculoma; Gardner syndrome; Muir Torre syndrome; Sebaceous tumours; Trichilemmoma

Indexed keywords

ALPHA2A INTERFERON; CELECOXIB; DACARBAZINE; DOXORUBICIN; ETRETIN; FLUOROURACIL; IFOSFAMIDE; INDOMETACIN; ISOTRETINOIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PODOPHYLLIN; RAPAMYCIN; RETINOIC ACID; ROFECOXIB; SULINDAC; TAMOXIFEN;

ADENOMATOUS POLYP; BIRT HOGG DUBE SYNDROME; CANCER SURGERY; CARBON DIOXIDE LASER; CHEMOPROPHYLAXIS; CHEMOSURGERY; COLORECTAL ADENOMA; COMBINATION CHEMOTHERAPY; COWDEN SYNDROME; CRYOTHERAPY; DESMOID TUMOR; DRUG EFFICACY; ERBIUM YAG LASER; GARDNER SYNDROME; GENE MUTATION; HAIR FOLLICLE; HUMAN; KERATOACANTHOMA; LASER SURGERY; MONOTHERAPY; MUIR TORRE SYNDROME; NONHUMAN; OSTEOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEBACEOUS GLAND TUMOR; SKIN TUMOR; TRICHILEMMOMA;

BIOLOGICAL MARKERS; EPIDERMAL CYST; GARDNER SYNDROME; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; MUIR-TORRE SYNDROME; NEOPLASMS, ADNEXAL AND SKIN APPENDAGE; SEBACEOUS GLAND NEOPLASMS; SKIN NEOPLASMS;

EID: 77749293070     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2009.03420.x     Document Type: Review

References (77)

1. Winship I, Dudding T. Lessons from the skin-cutaneous features of familial cancer. Lancet Oncol 2008 9 : 462 472.
2. Lee D, Grossman M, Schneiderman P, Celebi J. Genetics of skin appendage neoplasms and related syndromes. J Med Genet 2005 42 : 811 819.
3. Caputo R, Tadini G. Atlas of Genodermatoses. Taylor & Francis, UK, 2006.
4. Cribier B. Quand le diagnostic d'une tumeur annexielle peut sauver la vie du patient. Ann Dermatol Venereol 2009 136 : 125 132.
5. McKee, Calonje E, Granter S. Pathology of the Skin With Clinical Correlations, 3rd edn. Elsevier, Mosby, 2005.
6. Fistarol S, Anliker M, Itin P. Cowden disease or multiple hamartomata syndrome - cutaneous clues to internal malignancy. Eur J Dermatol 2002 12 : 412 421.
7. Lloyd KM, Denis M. Cowden's disease. A possible new symptom complex with multiple system involvement. Ann Intern Med 1963 58 : 136 142.
8. Starinck T, Hausman R. The cutaneous pathology of facial lesions in Cowden's disease. J Cutan Pathol 1984 11 : 331 337. (Pubitemid 14020714)
9. Salem O, Steck W. Cowden's disease (multiple hamartomata syndrome). A case report and review of the English literature. J Am Acad Dermatol 1983 8 : 686 696.
10. Starinck T, van der Veen J, Arwert F et al. The Cowden syndrome: a clinical and genetic study in 21 patients. Clinical Genet 1986 29 : 222 233.
11. Starinck T, Hausman R. The cutaneous pathology of extrafacial lesions in Cowden's disease. J Cutan Pathol 1984 11 : 338 344. (Pubitemid 14020715)
12. Ruhoy S, Thomas D, Nuovo G. Multiple inverted follicular keratoses as a presenting sign of Cowden's syndrome: case report with human papillomavirus studies. J Am Acad Dermatol 2004 51 : 411 415.
13. Pilarski R. Cowden's syndrome: a critical review of the clinical literature. J Genet Couns 2009 18 : 13 27.
14. Happle R. Linear Cowden nevus: a new distinct epidermal nevus. Eur J Dermatol 2007 17 : 133 136. (Pubitemid 46456762)
15. Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 2000 37 : 828 830.
16. Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumor syndrome. J Med Genet 2004 41 : 323 326.
17. Waite K, Eng C. Protean PTEN: form and function. Am J Hum Genet 2002 70 : 829 844.
18. Eng C. PTEN: one gene, many syndromes. Hum Mutat 2003 22 : 183 198.
19. Squarize C, Castilho R, Gutkind J. Chemoprevention and treatment of experimental Cowden's disease by mTOR inhbition with rapamycin. Cancer Res 2008 68 : 7066 7072.
20. Scheper M, Nikitakis N, Sarlani E, Sauk J, Meiller T. Cowden syndrome: report of a case with immunohistochemical analysis and review of the literature. Oral Med Oral Pathol Oral Radol Endod 2006 101 : 625 631.
21. Krymskaya V, Goncharova E. PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle 2009 8 : 403 413.
22. Gustafson S, Zbuk K, Scacheri C, Eng C. Cowden's syndrome. Semin Oncol 2007 34 : 428 434.
23. Ni Y, Zbuk K, Sadler T et al. Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. Am J Hum Genet 2008 83 : 261 268.
24. Ponti G, Ponz de Leon M. Muir-Torre syndrome. Lancet Oncol 2005 12 : 980 987.
25. Ponti G, Losi L, Di Gregorio C et al. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry. Cancer 2005 103 : 1018 1025.
26. Akhtar S, Oza K, Khan S, Wright J. Muir-Torre syndrome: case report of a patient with concurrent jejunal and ureteral cancer and a review of the literature. J Am Acad Dermatol 1999 41 : 681 686.
27. Cohen P, Kohn S, Kurzrock R. Association of sebaceous gland and internal malignancy: the Muir-Torre syndrome. Am J Med 1991 90 : 606 613.
28. Kruse R, Rutten A, Lamberti C et al. Muir-Torre phenotype has a frequency of DNA mismatch-repair gene mutations similar to that in hereditary non-polyposis colorectal cancer families defined by the Amsterdam criteria. Am J Hum Genet 1998 63 : 63 70.
29. Mathiak M, Rütten A, Mangold E et al. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test. Am J Surg Pathol 2002 26 : 338 343.
30. Abbas O, Mahalingam M. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm. J Cutan Pathol 2009 36 : 613 619.
31. South C, Hampel H, Comeras I, Westman J, Frankel W, de la Chapelle A. The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natl Cancer Inst 2008 100 : 277 281.
32. Schwartz R, Torre D. The Muir-Torre syndrome. A 25-year retrospect. J Am Acad Dermatol 1995 33 : 90 104.
33. Buitrago W, Joseph A. Sebaceous carcinoma: the great masquerader: emerging concepts in diagnosis and treatment. Dermatol Ther 2008 21 : 459 466.
34. Spielvogel R, de Villez R, Roberts L. Oral isotretinoin therapy for familial Muir-Torre syndrome. J Am Acad Dermatol 1985 12 : 475 478.
35. Graefe T, Wollina U, Schulz H, Burgdorf W. Muir-Torre syndrome - treatment with isotretinoin and interferon alpha-2a can prevent tumor development. Dermatology 2000 200 : 331 333.
36. Levi Z, Hazazi R, Kedar-Barnes I et al. Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome. Am J Transplant 2007 7 : 476 479.
37. Narisawa Y, Kohda H. Cutaneous cysts of Gardner's syndrome are similar to follicular stem cells. J Cutan Pathol 1995 22 : 115 121.
38. Gardner E, Richards R. Multiple cutaneous and subcutaneous lesions occurring simultaneously with hereditary polyposis and osteomatosis. Am J Hum Genet 1953 5 : 139 147.
39. Galiatsatos P, Foulkes W. Familial adenomatous polyposis. Am J Gastroenterol 2006 101 : 385 398.
40. Al-Sukhni W, Aronson M, Gallinger S. Hereditary colorectal cancer syndromes: familial adenomatous polyposis and Lynch syndrome. Surg Clin North Am 2008 88 : 819 844.
41. Bisgaard M, Bulow S. Familal adenomatous polyposis (FAP): genotype correlation to FAP phenotype with osteomas and sebaceous cysts. Am J Med Genet 2006 140 : 200 204.
42. Campos F, Habr-Gama A, Kiss D, Atui F, Katayama F, Gama-Rodrigues J. Manifestaçôes extracolônicas da polipose adenomatosa familiar. Arq Gastroenterol 2003 40 : 92 98.
43. Groen E, Roos A, Muntinghe F et al. Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol 2008 15 : 2439 2450.
44. Pujol R, Casanoja J, Edigo R, Moragas J. Multiple familial pilomatricomas: a cutaneous marker for Gardner syndrome? Ped Dermatol 1995 12 : 331 335.
45. Coffin C, Hornick J, Zhou H, Fletcher D. Gardner fibroma: a clinicopathological and immunohistochemical analysis of 45 patients with 57 fibromas. Am J Surg Pathol 2007 31 : 410 416.
46. Lipton L, Tomlinson I. The genetics of FAP and FAP-like syndromes. Fam Cancer 2006 5 : 221 226.
47. Goss K, Groden J. Biology of the Adenomatous Polyposis tumor suppressor gene. J Clin Oncol 2000 18 : 1967 1979.
48. Lefevre J, Parc Y, Svrcek M et al. APC, MYH, and the correlation genotype-phenotype in colorectal polyposis. Ann Surg Oncol 2009 16 : 871 877.
49. Souglakos J. Genetic alterations in sporadic and hereditary colorectal cancer: implementations for screening and follow-up. Dig Dis 2007 25 : 9 19.
50. Baglioni S, Melean G, Gensini F et al. A kindred with MYH-associated polyposis and pilomatricomas. Am J Med Genet A 2005 134 : 212 214.
51. Ajith Kumar V, Gold J, Mallon E, Thomas S, Hodgson S. Sebaceous adenomas in an MYH associated polyposis patient of Indian (Gujarati) origin. Fam Cancer 2008 7 : 187 189.
52. Ponti G, Ponz de Leon M, Maffei S et al. Attenuated familial adenomatous polyposis and Muir-Torre syndrome linked to compound biallelic constitutional MYH gene mutations. Clin Genet 2005 68 : 442 447.
53. Nieuwenhuis M, Vasen H. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis: a review of the literature. Crit Rev Hematol Oncol 2007 61 : 153 161.
54. Wijn M, Keller J, Giardiello F, Brand H. Oral and maxillofacial manifestations of familial adenomatous polyposis. Oral Dis 2007 13 : 360 365.
55. Lynch PM. Chemoprevention with special reference to inherited colorectal cancer. Fam Cancer 2008 7 : 59 64.
56. Merg A, Lynch H, Lynch J et al. Hereditary colon cancer. Part I Curr Probl Surg 2005 42 : 195 256.
57. King J, Dozois R, Lindor N, Ahlquist D. Care of patients and their families with familial adenomatous polyposis. Mayo Clin Proc 2000 75 : 57 67.
58. Rozen P, Macrae F. Familial adenomatous polyposis: the practical applications of clinical and molecular screening. Fam Cancer 2006 5 : 227 235.
59. Bhama P, Chugh R, Baker L, Doherty G. Gardner's syndrome in a 40-year-old woman: successful treatment of locally aggressive desmoid tumors with cytotoxic chemotherapy. World J Surg Oncol 2006 4 : 96.
60. Zbar B, Alvord W, Glenn G et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. Cancer Epidemiol Biomarkers Prev 2002 11 : 393 400.
61. Adley B, Smith N, Nayar R, Yang X. Birt-Hogg-Dubé syndrome. Clinicopathologic findings and genetic alterations. Arch Pathol Lab Med 2006 130 : 1865 1870.
62. Leter E, Koopmans A, Gille JJ et al. Birt-Hogg-Dube syndrome: clinical and genetic studies of 20 families. J Invest Dermatol 2008 128 : 45 49.
63. Toro J, Wei M, Glenn G et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J Med Genet 2008 45 : 321 331.
64. Vincent A, Farley M, Chan E, James W. Birt-Hogg-Dube syndrome: a review of the literature and the differential diagnosis of firm facial papules. J Am Acad Dermatol 2003 49 : 698 705.
65. Hornstein O, Knickenberg M. Multiple dermal perifollicular fibromas with polyps of the colon - report of a peculiar clinical syndrome. Acta Hepatogastroenterol 1976 23 : 53 58.
66. Schultz T, Hartschuh W. Birt-Hogg Dubé/Hornstein-Knickenberg- syndrome are the same. Diffferent sectioning technique as the cause of different histology. J Cutan Pathol 1999 26 : 55 61.
67. Nickerson M, Warren M, Toro J et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2002 2 : 157 164.
68. Palmirotta R, Donati P, Savonarola A, Cota C, Ferroni P, Guadagni F. Birt-Hogg-Dubé (BHD) syndrome: report of two novel germline mutations in the folliculin (FLCN) gene. Eur J Dermatol 2008 18 : 382 386.
69. Warren M, Torres-Cabala C, Turner ML et al. Expression of Birt-Hogg-Dube gene mRNA in normal and neoplastic human tissues. Mod Pathol 2004 17 : 998 1011.
70. Hartman T, Nicolas E, Klein-Szanto A et al. The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis. Oncogene 2009 28 : 1594 1604.
71. Chen J, Futami K, Petillo D et al. Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia. PLoS ONE 2008 3 : e3581.
72. Yang Y, Padilla-Nash H, Vira M et al. The UOK 257 cell line: a novel model for studies of the human Birt-Hogg-Dubé gene pathway. Cancer Genet Cytogenet 2008 180 : 100 109.
73. Gunji Y, Akiyoshi T, Sato T et al. Mutations of the Birt-Hogg-Dube gene in patients with multiple lung cysts and recurrent pneumothorax. J Med Genet 2007 44 : 588 593.
74. Schaffer J, Gohara M, McNiff J, Aasi S, Dvoretzky I. Multiple facial angiofibromas: a cutaneous manifestation of Birt-Hogg Dubé syndrome. J Am Acad Dermatol 2005 53 : S108 S111.
75. Welsch M, Krunic A, Medenica M. Birt-Hogg-Dubé syndrome. Int J Dermatol 2005 44 : 668 673.
76. Farrant PB, Emerson R. Hyfrecation and curettage as a treatment for fibrofolliculomas in Birt-Hogg-Dube syndrome. Dermatol Surg 2007 33 : 1287 1288.
77. Baba M, Furihata M, Hong S et al. Kidney-targeted Birt-Hogg-Dubé gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst 2008 100 : 140 154.